Records containing: Pancreatic Adenocarcinoma
This is the wording recorded or indexed by the source. An agency index term is not necessarily an authorised indication. Co-listed drug names are not linked to this term as a treatment relationship.
Follow recorded terms in Drug Alerts for Android. Free includes unlimited local condition follows and an on-open recent-record watchlist. Plus adds no ads and personal organization tools.
All
FDA submission records
EMA medicine records
ClinicalTrials.gov record updates
ClinicalTrials.gov records with results posted
-
CLINICAL_TRIALS study record update · 2026-09-15Prehabilitation for Elderly Patients With Advanced Epithelial Ovarian, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer Undergoing Neoadjuvant Chemotherapy
-
CLINICAL_TRIALS study record update · 2026-09-14ORACLE: Observation of ResiduAl Cancer With Liquid Biopsy Evaluation
-
CLINICAL_TRIALS study record update · 2026-09-11A Phase 1/1b Study of ASP2138 as Monotherapy and in Combination With Pembrolizumab and mFOLFOX6 or Ramucirumab and Paclitaxel in Participants With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination With mFOLFIRINOX in Participants With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression
-
CLINICAL_TRIALS study record update · 2026-09-11A Phase II Study of FOLFIRINOX Combined With the Glycogen Synthase Kinase-3 Beta (GSK-3 β) Inhibitor Elraglusib and the Transforming Growth Factor-β (TGF-β) Inhibitor Losartan in Patients With Untreated Metastatic Pancreatic Adenocarcinoma
-
CLINICAL_TRIALS study record update · 2026-09-02A Phase 1 Multiple Expansion Cohort Trial of MRTX1719 in Patients With Advanced Solid Tumors With Homozygous MTAP Deletion
- Organize your saved records without ads with Plus.
-
CLINICAL_TRIALS study record update · 2026-09-01Expanded Access Program to Treat Patients With Previously Treated Metastatic Pancreatic Adenocarcinoma With Daraxonrasib
-
CLINICAL_TRIALS study record update · 2026-09-01GI-06: The Impact of Perioperative Hydrocortisone on Patients Undergoing Partial Pancreatectomy
-
CLINICAL_TRIALS study record update · 2026-08-26Phase I Study of Th-1 Dendritic Cell Immunotherapy in Combination With Standard Chemotherapy for the Adjuvant Treatment of Pancreatic Adenocarcinoma (DECIST)
-
CLINICAL_TRIALS study record update · 2026-08-25Observational Study to Analyze the Outcomes of Subjects Who - Based Upon Their Sufficiently Elevated Risk for the Development of Pancreatic Adenocarcinoma- Elect to Undergo Early Detection Testing
-
CLINICAL_TRIALS study record update · 2026-04-27Circulating Tumor Cell and Tumor Tissue Models for Predicting Effective Pancreatic Cancer Response
-
CLINICAL_TRIALS study record update · 2026-04-24A Phase II Multicenter Trial of ESK981 in Patients With Select Solid Tumors
-
CLINICAL_TRIALS study record update · 2026-04-23Superior Mesenteric Artery First Versus Standard Approach in Pancreaticoduodenectomy
-
CLINICAL_TRIALS study record update · 2026-04-23A Phase 1/2 Open-label Multicenter Study to Assess the Safety, Pharmacokinetics, and Anti-tumor Activity of GTAEXS617 in Patients With Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2026-04-23Subjects With Advanced Basal-like Pancreatic Adenocarcinoma Treated With Gemcitabine, Erlotinib and Nab-paclitaxel (PANGEA) Versus Subjects With Classical Pancreatic Adenocarcinoma Treated With Triplet Standard of Care Therapy.
-
CLINICAL_TRIALS study record update · 2026-04-22A Phase 1/1b Study of ASP2138 as Monotherapy and in Combination With Pembrolizumab and mFOLFOX6 or Ramucirumab and Paclitaxel in Participants With Metastatic or Locally Advanced Unresectable Gastric or Gastroesophageal Junction (GEJ) Adenocarcinoma and in Combination With mFOLFIRINOX in Participants With Metastatic or Locally Advanced Unresectable Pancreatic Adenocarcinoma Whose Tumors Have Claudin (CLDN) 18.2 Expression
-
CLINICAL_TRIALS study record update · 2026-04-22Prospective Validation of an EHR-based Model to Predict Pancreatic Cancer Risk Using Multicenter US Data
-
CLINICAL_TRIALS study record update · 2026-04-22A Phase II Study of Paclitaxel Protein Bound + Gemcitabine + Cisplatin + Paricalcitol as Pre-operative Treatment in Patients With Untreated Resectable, Borderline Resectable and Locally Advanced Adenocarcinoma of the Pancreas
-
CLINICAL_TRIALS study record update · 2026-04-20A Phase 1 Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
-
CLINICAL_TRIALS study record update · 2026-04-16Tissue Micro-RNA Profile Collected Through Endoscopic Ultrasonography Fine-Needle-Aspiration (EUS-FNA) In Pancreatic Adenocarcinoma And Its Impact On Survival And Prognosis
-
CLINICAL_TRIALS study record update · 2026-04-15Phase II Study of Stereotactic Body Radiotherapy Plus FAK and RAF/MEK Inhibition in Advanced Pancreatic Adenocarcinoma
-
CLINICAL_TRIALS study record update · 2026-04-15A Phase 1b/2 Open-label Study to Assess the Safety and Efficacy of ASP546C in Participants With CLDN18.2-expressing Locally Advanced Unresectable or Metastatic Gastroesophageal Adenocarcinoma, Pancreatic Adenocarcinoma or Other Solid Tumor Types
-
CLINICAL_TRIALS study record update · 2026-04-15An Open-label, Phase 1, Multicenter Study to Evaluate the Safety and Preliminary Anti-tumor Activity of NT-175 in Human Leukocyte Antigen-A*02:01-Positive Adult Subjects With Unresectable, Advanced and/or Metastatic Solid Tumors That Are Positive for the TP53 R175H Mutation
-
CLINICAL_TRIALS study record update · 2026-04-15EUS-guided PORtal Vein Sampling for Isolation, Enumeration and Profiling of Circulating Tumor Cells in Pancreatic Cancer Patients
-
CLINICAL_TRIALS study record update · 2026-04-15PancStrength: Safety, Feasibility, and Acceptability of a Tele-Exercise Resistance Training Intervention During Pancreatic Cancer Treatment
-
CLINICAL_TRIALS study record update · 2026-04-13A Phase II Study of FOLFIRINOX Combined With the Glycogen Synthase Kinase-3 Beta (GSK-3 β) Inhibitor Elraglusib and the Transforming Growth Factor-β (TGF-β) Inhibitor Losartan in Patients With Untreated Metastatic Pancreatic Adenocarcinoma